GUIDELINES ON COMPANY PROCEDURES RELATING TO THE 2021 ABPI CODE OF PRACTICE FOR THE PHARMACEUTICAL INDUSTRY
Published 7 July 2021
Please click here for more details
The Prescription Medicines Code of Practice Authority
The Prescription Medicines Code of Practice Authority (PMCPA) is the self-regulatory body which administers the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry, independently of the ABPI. It was established by the ABPI on 1 January 1993.
The Authority is responsible for the provision of advice, guidance and training on the Code as well as for the complaints procedure. It is also responsible for arranging for conciliation between companies when requested to do so and for arranging for the scrutiny of advertising and meetings on a regular basis.
The PMCPA was established by The Association of the British Pharmaceutical Industry (ABPI) to operate the ABPI Code of Practice for the Pharmaceutical Industry, independently of the ABPI.
The aim of the Code is to ensure that the promotion of medicines by the pharmaceutical industry is carried out within a robust framework, to support high quality patient care.
Code of Practice Seminars
- dates under review due to COVID-19
ABPI Examination for Medical Representatives
More information is available on the ABPI website, link below
To extend the time available to take the examination an application for an extension should be made on the form on this website, link below
The extension request should preferably be made by the company rather than the representative.
In house training
- under review due to COVID-19
For more information see Training Opportunities.
Novartis, Camurus, Pfizer and Boehringer Ingelheim have been named in advertisements for breaches of the ABPI Code
21 October 2021read more
LEO Pharma, Norgine, Daiichi-Sankyo, Novartis, Sanofi, Consilient, and Pharmasure have been named in advertisements for breaches of the ABPI Code
02 August 2021read more